| Li, Jian |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT05262010: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years |
|
|
| Recruiting | 3 | 13500 | RoW | 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), placebo | National Vaccine and Serum Institute, China, Chengdu Institute of Biological Products Co.,Ltd., Simoon Record Pharma Information Consulting Co., Ltd., Beijing Kantorico Statistical Technology Co., Ltd., Guangxi Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Shanxi Center for Disease Control and Prevention | HPV InfectioN, HPV-Related Carcinoma | 06/28 | 06/28 | | |
| Not yet recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
| Recruiting | 2 | 42 | RoW | Idarubicin and cytarabine induction | Peking Union Medical College Hospital | Acute Myeloid Leukemia | 10/21 | 12/21 | | |
NCT04121819: AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis |
|
|
| Recruiting | 2 | 40 | RoW | Cytarabine | Peking Union Medical College Hospital | Langerhans Cell Histiocytosis | 12/21 | 12/21 | | |
NCT04120519: Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis |
|
|
| Recruiting | 2 | 20 | RoW | thalidomide combined with dexamethasone and cyclophosphamide | Peking Union Medical College Hospital | Langerhans Cell Histiocytosis | 12/21 | 12/21 | | |
NCT03982771: BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) |
|
|
| Recruiting | 2 | 30 | RoW | Bortezomib, Cyclophosphamide, Dexamethason | Peking Union Medical College Hospital | Idiopathic Multicentric Castleman's Disease | 01/22 | 01/23 | | |
NCT05345522: A Study of Anti-IL-6R mAb Injection in Patients With iMCD |
|
|
| Recruiting | 2 | 9 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg | Beijing VDJBio Co., LTD. | Idiopathic Multicentric Castleman's Disease | 11/22 | 12/24 | | |
NCT04474938: Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis |
|
|
| Active, not recruiting | 2 | 40 | RoW | Daratumumab, Bortezomib, Dexamethasone | Peking Union Medical College Hospital, Xian-Janssen Pharmaceutical Ltd. | Amyloidosis; Systemic | 06/23 | 03/24 | | |
NCT04716634: Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors |
|
|
| Completed | 2 | 84 | RoW | Tislelizumab, BGB-A317, Fruquintinib, HMPL-013 | BeiGene, Hutchison Medipharma Limited | Advanced Solid Tumors | 02/24 | 02/24 | | |
NCT05092815: The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation |
|
|
| Active, not recruiting | 2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH, ECD | 06/24 | 10/24 | | |
iMCD, NCT04743687: Zanuburutinib in Relapsed and Refractory a Prospective, Single-center, Single-arm Trial |
|
|
| Recruiting | 2 | 30 | RoW | Zanubrutinib, brukinsa | Peking Union Medical College Hospital | Idiopathic Multicentric Castleman's Disease | 01/25 | 01/25 | | |
NCT06772233: A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment |
|
|
| Recruiting | 2 | 82 | RoW | regorafenib combined with envafolimab, Control Group | Peking University | Metastatic Gastrointestinal Stromal Tumors (GIST) | 08/25 | 08/26 | | |
NCT05248633: Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma |
|
|
| Recruiting | 2 | 220 | RoW | radiotherapy, Bortezomib Injection, Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Solitary Plasmacytoma | 04/26 | 10/26 | | |
| Not yet recruiting | 2 | 80 | RoW | KN026, KN046, XELOX | Peking University Cancer Hospital & Institute | HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer | 12/26 | 12/26 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
| Recruiting | 1/2 | 29 | RoW | KQ-2003 CAR T-cells | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Multiple Myeloma | 03/26 | 03/26 | | |
NCT06526819: SMP-3124LP in Adults With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | Japan, US | SMP3124LP | Sumitomo Pharma America, Inc. | Solid Tumor | 12/28 | 05/29 | | |
NCT03692663: Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 9 | RoW | TABP EIC, Cyclophosphamide, fludarabine | Allife Medical Science and Technology Co., Ltd., Tianjin People's Hospital | Metastatic Castration-resistant Prostate Cancer | 06/23 | 06/24 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT06518876: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome |
|
|
| Not yet recruiting | 1 | 21 | RoW | KQ-2003 CAR T-cells | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | POEMS Syndrome | 12/27 | 12/27 | | |
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma |
|
|
| Active, not recruiting | 1 | 39 | Japan, US | DSP-0390 | Sumitomo Pharma America, Inc. | High Grade Glioma, Glioblastoma Multiforme | 09/26 | 10/26 | | |
| Active, not recruiting | 1 | 31 | US | TP-1454 monotherapy | Sumitomo Pharma America, Inc. | Advanced Solid Tumor, Anal Cancer | 03/25 | 05/25 | | |
NCT06137521: Risk Factors and Outcomes in Coronary Chronic Total Occlusion |
|
|
| Recruiting | N/A | 3000 | RoW | Coronary angiography | Ruijin Hospital | Chronic Total Occlusion, Coronary Artery Disease | 12/26 | 03/27 | | |
NCT05439226: Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease |
|
|
| Recruiting | N/A | 120 | RoW | CMNT diet | State Key Laboratory of Subhealth Intervention Technology | Type 2 Diabetes | 06/23 | 05/24 | | |
| Recruiting | N/A | 3000 | RoW | | Ruijin Hospital | Coronary Artery Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Obesity, Metabolic Syndrome | 12/25 | 12/25 | | |
NCT06549907: A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy |
|
|
| Recruiting | N/A | 50 | RoW | Multi-omics testing, MRI | Peking University Cancer Hospital & Institute | MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy | 09/28 | 09/28 | | |
NCT06489613: Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology. |
|
|
| Not yet recruiting | N/A | 15600 | RoW | M protein detection by iMS-LC Assay | Jian Li | M Protein, Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance | 12/24 | 06/25 | | |
RECOGNIZE-IV, NCT06793787: Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV |
|
|
| Recruiting | N/A | 200 | RoW | | Ruijin Hospital | Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS), Chronic Coronary Syndrome | 12/25 | 12/27 | | |
RECOGNIZE-III, NCT06793774: Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III |
|
|
| Recruiting | N/A | 300 | RoW | | Ruijin Hospital | Coronary Artery Disease, Coronary Atheroscleroses, Acute Coronary Syndromes (ACS) | 12/25 | 12/27 | | |
NCT06443307: Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan |
|
|
| Recruiting | N/A | 933 | RoW | Irinotecan Liposome | Peking University | Colorectal Cancer, Solid Tumor | 07/26 | 08/26 | | |
| Recruiting | N/A | 90 | RoW | Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy, High-dose cytarabine | Ruijin Hospital | Acute Myeloid Leukemia | 09/26 | 02/28 | | |
NCT06458257: The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 50 | RoW | Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy | Ruijin Hospital | Acute Myeloid Leukemia | 12/26 | 12/28 | | |
NCT05717790: Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 288 | RoW | Nimotuzumab, h-R3, BIOMAb EGFR, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Fourth Affiliated Hospital of Guangxi Medical University, People's Hospital of Baise, Second Affiliated Hospital of Guangzhou Medical University, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin Medical University, China, LiuZhou People's Hospital, The First People's Hospital of Qinzhou, Wuzhou Red Cross Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities | Nasopharyngeal Carcinoma by AJCC V8 Stage | 11/24 | 11/27 | | |
| Recruiting | N/A | 50 | US | Schedule Change, No Schedule Change | University of California, Los Angeles | Work-Related Condition | 03/25 | 09/25 | | |
NCT05227378: Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer |
|
|
| Not yet recruiting | N/A | 36 | RoW | neoantigen tumor vaccine with or without PD-1/L1 | Shen Lin, NeoCura | Gastric Cancer | 03/25 | 08/25 | | |
RECOGNIZE-I, NCT05884008: Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I |
|
|
| Recruiting | N/A | 300 | RoW | | Ruijin Hospital | Coronary Artery Disease | 06/25 | 12/25 | | |
| Recruiting | N/A | 2000 | RoW | | Ruijin Hospital | Coronary Artery Disease | 09/25 | 12/25 | | |
NCT06009718: Artificial Intelligence (AI) Analysis of Synchronized Phonocardiography (PCG) and Electrocardiogram(ECG) |
|
|
| Recruiting | N/A | 3000 | RoW | | Ruijin Hospital | Heart Failure | 06/27 | 06/28 | | |
NCT04525209: Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma |
|
|
| Not yet recruiting | N/A | 200 | RoW | No intervention | Ruijin Hospital | Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics | 12/22 | 12/22 | | |
